Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × enzastaurin × CNS × Clear all

Phase

Phase 2 3 Phase 1 2 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1 CNS 1

Conditions

Interventions

Radiotherapy 64 Temozolomide 59 Vincristine 33 Cyclophosphamide 32 Carboplatin 30 Radiosurgery 26 Etoposide 25 Cisplatin 25 Lomustine 24 Magnetic Resonance Spectroscopy 19 Filgrastim 17 Doxorubicin 15 Bevacizumab 15 Radiation 13 Specimen Handling 12 Granulocyte Colony-Stimulating Factor 12 Surgical Procedures, Operative 11 Isotretinoin 11 Melphalan 10 Carmustine 10 Procarbazine 9 Platinum 9 Peripheral Blood Stem Cell Transplantation 9 Chemotherapy, Adjuvant 9 etoposide phosphate 7 Topotecan 7 1,2-diaminocyclohexaneplatinum II citrate 7 sargramostim 6 Thiotepa 6 Radiotherapy, Intensity-Modulated 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00295815 2019-09-12

Enzastaurin Versus Lomustine in Glioblastoma

Eli Lilly and Company

Phase 3 Completed

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡